Galderma CareConnect hits milestoneGalderma’s patient access program Galderma CareConnect recently passed the 1,000,000 filled prescriptions.
Refyne, Defyne: New fillers, unique benefits?Dr. Joe Niamtu offers his opinion on how these “flexible” fillers fit into the overall HA category.
Galderma launches two new dermal fillersGalderma receives FDA approval for Restylane Refyne and Defyne, two next-generation HA fillers.
Galderma, Mentor Worldwide collaborationIt’s a move to try to garner both surgeon and consumer loyalty. Will it work?
Neurotoxin pipeline advances, stay wary of counterfeitsAs the neurotoxin market is set for expansion, so expands the market of counterfeit products. One expert reviews the innovative options coming up through the pipeline and cautions colleagues about the risks associated with counterfeits.
Galderma, ZELTIQ collaborate on aesthetics in U.S.It's not a merger, but a strategic collaboration between Galderma and ZELTIQ to promote CoolSculpting and Dysport.
Antibiotic-free treatment effective, safe for moderate-to-severe acne“The increased strength of adapalene (a retinoid) is a valuable ingredient to explore in view of the growing incidence of drug resistance and the fact that it apparently worked in moderate to severe acne patients is a very good sign," says an expert. Learn more.
It's rosacea, not acneNearly half of rosacea patients thought they had acne before being diagnosed. Learn how to explain the difference between rosacea and acne to patients and help them get the care they need.
FDA Approves Ivermectin 1% Cream for Rosacea
FDA Approves Ivermectin 1% Cream for RosaceaLead author and a Galderma consultant dermatologist Linda Stein Gold, M.D. writes to Dermatology Times that results from Soolantra (ivermectin) Cream, 1% were seen in clinical studies as early as week two, with continuous improvement in patients with inflammatory lesions of rosacea.
FDA grants orphan drug status for congenital ichthyosis treatmentThe Food and Drug Administration has granted orphan drug designation to Galderma’s trifarotene molecule for the treatment of congenital ichthyosis.